Table 2.
Re-stratification matrix of the number of MDS patients classified in each of the WHO 2016 classification (column) and each of the WHO 2022 classification (row).
| WHO-2016, n | MDS-5q | MDS-RS-SLD | MDS-RS-MLD | MDS-SLD | MDS-MLD | MDS-EB1 | MDS-EB2 | MDS-U | Number of patients, n (%) |
|---|---|---|---|---|---|---|---|---|---|
| WHO-2022, n | |||||||||
| MDS-5q | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11(1.3) |
| MDS-SF3B1 | 0 | 21 | 24 | 3 | 21 | 0 | 0 | 1 | 70 (8.6) |
| MDS-biTP53 | 1 | 1 | 0 | 1 | 14 | 10 | 24 | 2 | 53 (6.5) |
| MDS-LB | 0 | 0 | 0 | 34 | 254 | 0 | 0 | 5 | 293 (36) |
| MDS-h | 0 | 0 | 0 | 11 | 67 | 0 | 0 | 2 | 80 (9.8) |
| MDS-IB1 | 0 | 0 | 0 | 0 | 0 | 161 | 0 | 0 | 161 (19.8) |
| MDS-IB2 | 0 | 0 | 0 | 0 | 0 | 0 | 103 | 0 | 103 (12.7) |
| MDS-f | 0 | 0 | 0 | 0 | 0 | 20 | 22 | 0 | 42 (5.2) |
| Number of patients, n (%) | 12 (1.5) | 22 (2.7) | 24 (3.0) | 49 (6) | 356 (43.8) | 191 (23.5) | 149 (18.3) | 10 (1.2) | 813 |
WHO World Health Organization, MDS myelodysplastic syndromes(neoplasms), MDS-U MDS unclassifiable, SLD single lineage dysplasia, MLD multilineage dysplasia, RS-SLD ring sideroblasts with SLD, RS-MLD ring sideroblasts with MLD, EB1/2 excess blasts type 1/2, 5q- isolated 5q deletion, biTP53 biallelic TP53 inactivation, LB low blasts, MDS-SF3B1 MDS with low blasts and SF3B1 mutation, MDS-h MDS hypoplastic, IB1/2: increased blasts type1/2, MDS-f MDS with fibrosis.